Figure 3 | Scientific Reports

Figure 3

From: Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors

Figure 3

Incidence of macular atrophy during the course of anti-VEGF treatment. Incidence of new macular atrophy was 11.5% at year one, 15.4% throughout years 2–4, and 22.4% at year 5 (grey line). Until year 4, a similar atrophy incidence could be detected in eyes with type 1 and 2 CNV at baseline. At year five, eyes with a type 2 CNV at baseline showed a tendency towards more atrophy than type 1 lesions (p = 0.17).

Back to article page